The purpose of this study is to discuss recent data relating to the treatment of cardiac arrest survivors. This is a rapidly evolving component of resuscitation medicine that impacts significantly on the quality of survival after cardiac arrest.
Introduction
Survival rates following in-hospital and out-of-hospital cardiac arrest (OHCA) remain disappointingly low [1,2 ], but there is good evidence that interventions applied after return of spontaneous circulation (ROSC) significantly influence the chances of survival with good neurological outcome [3, 4 ] . Approximately one-third of patients admitted to an ICU after cardiac arrest survive to be discharged from hospital [5] , but there is considerable variation in postcardiac arrest treatment and patient outcome between institutions [6 ,7 ] . The prolonged period of systemic ischaemia during cardiac arrest and the subsequent reperfusion response that occurs after ROSC precipitates a complex set of pathophysiological processes known as the postcardiac arrest syndrome (PCAS) [8 ] . This review will address recent advances in the treatment of survivors of cardiac arrest with specific attention to optimizing myocardial and neurological recovery. Recent data relating to prognostication in comatose survivors of cardiac arrest will also be highlighted.
Postcardiac arrest syndrome
The PCAS comprises postcardiac arrest brain injury, postcardiac arrest myocardial dysfunction, the systemic ischaemia/reperfusion response, and the persistent precipitating disease. A recent scientific statement from the International Liaison Committee on Resuscitation (ILCOR) and several other organizations provides comprehensive information about the epidemiology, pathophysiology, treatment, and prognostication of the PCAS [8 ].
Optimizing myocardial recovery after cardiac arrest
Acute changes in coronary plaque morphology are found in 40-86% of cardiac arrest survivors and in 15-64% of autopsy studies [9] . Early and complete restoration of perfusion is the fundamental goal of the treatment of STsegment elevation myocardial infarction (STEMI). Reperfusion can be achieved with primary percutaneous coronary intervention (PCI), fibrinolysis, or both [10 ] .
Fibrinolytic therapy results in full reperfusion in only 50-55% of cases, but with primary PCI, the success rate is higher than 90% [11 ] . Primary PCI is the preferred treatment if a first medical contact-to-balloon time of less than 90 min can be achieved [12, 13] . This is also likely to be true for those resuscitated from cardiac arrest associated with STEMI [14-16], but this hypothesis has never been tested in a randomized trial. The early postresuscitation 12-lead ECG is less reliable for predicting acute coronary occlusion than it is in those who have not had a cardiac arrest. It has been proposed that all comatose survivors of cardiac arrest from a likely cardiac cause should be considered for urgent coronary angiography and PCI [14] .
Arterial hypotension is common among cardiac arrest survivors admitted to the ICU: a recent large study [17 ] reported one or more documented SBP readings of less than 90 mmHg within 1 h of ICU admission in 47% of cases, and this was associated with a significantly higher mortality rate than among those who were not hypotensive (65 versus 37%; P < 0.01). The optimum postresuscitation blood pressure (BP) has not been defined and can vary among individuals. Early goal-directed therapy (EGDT) reduces mortality in patients with septic shock and, on the grounds that the PCAS shares many features with the sepsis syndrome, it has been postulated that EGDT can improve outcome in PCAS. A small study (n ¼ 36) [4 ] of EGDT (incorporating a target mean arterial BP of 80-100 mmHg) combined with therapeutic hypothermia showed a trend towards improved survival rates compared with historic controls.
Optimizing neurological outcome after cardiac arrest
Postcardiac arrest brain injury is a common cause of morbidity and mortality. In one study [18] of patients surviving to ICU admission but subsequently dying in hospital, brain injury was the cause of death in 68% after OHCA and in 23% after in-hospital cardiac arrest.
Controlled reoxygenation
Animal data indicate that too much oxygen during the initial stages of reperfusion exacerbates neuronal damage through production of free radicals and mitochondrial injury. During the initial phases of resuscitation, ventilation with the minimum fraction of inspired oxygen (FiO 2 ) required to maintain adequate oxygen saturation of arterial blood (94-96%), a technique known as controlled reoxygenation, may optimize neurological outcome [19] . On the basis of these data, unnecessary arterial hyperoxia should be avoided, particularly during the initial postcardiac arrest period. The British Thoracic Society recommends a target oxygen saturation of 94-98% for those critically ill patients not at risk of hypercapnic respiratory failure [20] .
Glucose control
Hyperglycaemia is common after cardiac arrest, and for nondiabetic patients, there is a U-shaped relationship between maximum and minimum blood glucose and hospital survival after adjustment for confounders: both high and low glucose values are associated with decreased odds of survival [5,21,22 ,23 ] . One, well known study [24] showed that tight blood glucose control (4.4-6.1 mmol/l or 80-110 mg/dl) with insulin reduced hospital mortality rates in surgical ICU patients. But a recent trial of over 6000 ICU patients reported an increased 90-day mortality among those randomized to glucose control in the range from 4.5 to 6.0 mmol/l (81-108 mg/dl) compared with those with a target blood glucose of 10.0 mmol/l (180 mg/dl) or less (27.5 versus 24.9%, P ¼ 0.02) [25 ] . Severe hypoglycaemia [blood glucose less than 2.2 mmol/l (40 mg/dl)] occurred in 6.8% of cases in the intensive control group and in 0.5% of the control group (P < 0.001).
In another randomized trial of medico-surgical ICU patients, which was stopped prematurely because of protocol violations, the rate of hypoglycaemia was higher in the intensive insulin group than the intermediate glucose control group (8.7 versus 2.7%, P < 0.0001), but the mortality was similar in the two groups [26 ] . The only prospective, randomized trial of glucose control in patients successfully resuscitated from OHCA showed no difference in 30-day mortality between those treated with strict glucose control [4-6mmol/l (72-108 mg/dl)] and those treated with moderate control [6-8 mmol/l (108-144 mg/dl)] [27] . Furthermore, the strict glucose control group showed an increase in serum neuron-specific enolase (NSE) between 24 and 48 h, suggesting more severe brain injury. Strict glucose control may limit the supply of glucose to the brain, which is an obligate glucose metabolizer, thus worsening brain injury. In his editorial, Padkin [23 ] concludes that 'patients successfully resuscitated following cardiac arrest should not be treated with strict glucose control targeting normoglycaemia but that a more moderate blood glucose target range of below 10 mmol/l (180 mg/dl) should be used'. Pending further data, this is likely to be the guideline adopted by most intensive care clinicians.
Therapeutic hypothermia
Therapeutic hypothermia is now generally accepted as part of a standardized treatment for comatose survivors of cardiac arrest [8 ,28,29,30 ,31 ] . There are multiple mechanisms by which mild hypothermia (32-348C) may improve neurological outcome in patients remaining comatose after cardiac arrest [32 ] . The proposed mechanisms of action of therapeutic hypothermia include decreased cerebral metabolism (by about 8% per 8C below 378C), reduced apoptosis, inhibition of the neuro-excitatory cascade, suppression of proinflammatory cytokines, reduced free-radical production, reduced vascular permeability following ischaemia-reperfusion injury, and improved brain glucose metabolism.
The use of therapeutic hypothermia is based mainly on evidence from one randomized trial [33] and a pseudorandomized trial [34] , which demonstrated an improvement in neurological outcome after discharge from hospital in patients who had an out-of-hospital ventricular fibrillation (VF) cardiac arrest, who were still comatose, and who were cooled to 32-348C for 12-24 h after ROSC. Two studies [35, 36] with historical control groups have also shown an improvement in neurological outcome after therapeutic hypothermia for comatose survivors of VF cardiac arrest.
The evidence for benefit of hypothermia after cardiac arrest from other rhythms and in a hospital setting is less robust, although this has not prevented clinicians from implementing the therapy in these settings [37 -39 ] . Five studies [3, [40] [41] [42] [43] with historical controls showed benefit after therapeutic hypothermia in comatose survivors of OHCA after all rhythm arrests. Two studies [44 ,45 ] with historical controls showed better neurological outcome after VF cardiac arrest but no difference after cardiac arrest from other rhythms. Two nonrandomized studies [46, 47] with concurrent controls suggested possible benefit of hypothermia following cardiac arrest from other initial rhythms in-hospital and out-of-hospital. In a retrospective, five-centre study [48 ] , the use of hypothermia after cardiac arrest in children was associated with higher mortality and worse functional outcome than with normothermia; however, hypothermia had been used in circumstances that were associated generally with a higher risk of a poor outcome. When adjusted for these confounders, there was no statistically significant difference in outcome between the hypothermia and normothermia groups. On the basis of these results, the authors recommend that a randomized controlled trial is needed to evaluate the use of hypothermia therapy after cardiac arrest in children.
The practical approach to therapeutic hypothermia can be divided into three parts: induction, maintenance, and rewarming [49 ] . Induction can be induced easily and inexpensively with intravenous ice-cold fluids (30 ml/kg of saline 0.9% or Ringer's lactate) [50-54,55 ,56,57 ,58 ] or traditional ice packs, placed in the groins, armpits, and around the neck and head. Rapid intravenous infusion of a large volume of ice-cold fluids is remarkably well tolerated immediately after ROSC [59 ] . Several studies have shown that hypothermia can be initiated before hospital admission [60] [61] [62] [63] . Out-of-hospital cooling can also be initiated with cooling pads [64] . By starting cooling before hospital admission, it is possible to achieve the target temperature more rapidly, which may maximize the neuroprotection provided by mild hypothermia [65 ] .
Ultimately, starting cooling during cardiac arrest may be most beneficial; animal data indicate that this may facilitate ROSC [66 ,67] and reduce myocardial infarction size [68 ] . However, using data from the Hypothermia after Cardiac Arrest (HACA) trial, Koreny et al. [69 ] showed that after successful resuscitation for ventricular fibrillation cardiac arrest, cooling did not influence infarct size. Nasopharyngeal cooling, achieved by instilling perfluorocarbon via nasal prongs, is a novel way of inducing hypothermia during cardiac arrest [37 ] . Animal data have been encouraging [70] , and the results of the first clinical trial [Pre-ROSC Intra-Nasal Cooling Effectiveness (PRINCE)] were presented at the Resuscitation Science Symposium in Orlando in November 2009. Initial cooling is facilitated by concomitant neuromuscular blockade with sedation to prevent shivering. The use of magnesium may improve the efficiency of cooling because it is a vasodilator and reduces the shivering threshold [28] . The use of surface counter warming will also reduce shivering during therapeutic hypothermia [71] . Surface or internal cooling devices can also be used alone or in combination with the above measures to facilitate induction [28, 72 ] . If indicated, the patient can be transferred safely to the angiography laboratory with ongoing cooling [39 ,73] . In the maintenance phase, a cooling method with effective temperature monitoring that avoids temperature fluctuations is preferred. This is best achieved with external or internal cooling devices that include continuous temperature feedback to achieve a set target temperature [74] . Typical external devices are cooling blankets [75] or pads with water-filled circulating systems [76 ] . Typical internal cooling devices include intravascular cooling catheters [77] , placed usually in the femoral or subclavian veins. However, less sophisticated methods, such as cold wet, blankets on the torso and around the extremities, or icepacks, combined with ice cold fluids, can also be effective; however, these methods may be more time-consuming for nursing staff, may result in greater temperature fluctuations, and do not enable controlled rewarming [72 ] . Ice-cold fluids alone cannot be used to maintain hypothermia [52] , but even the addition of simple ice packs may control the temperature adequately [58 ] . Recent data from Japan suggest that early attainment of a core temperature of 348C during extracorporeal cardiopulmonary resuscitation (CPR) and primary PCI has neurological benefits for patients with OHCA who fail to respond to conventional CPR [78 ] .
The rewarming phase can be achieved with either external or internal cooling devices (if these are used), or with other heating systems. The optimal rate of rewarming is not known, but the consensus is currently about 0.258C of warming per hour [28] . Particular care should be taken during the cooling and rewarming phases because metabolic rate, plasma electrolyte concentrations, and haemodynamics may change rapidly [28] . There are many well documented complications of therapeutic hypothermia (Table 1) 
Prognostication
Predicting the eventual outcome of those remaining comatose after initial resuscitation from cardiac arrest remains problematic [79 ] . Neurological examination does not reliably prognosticate futility in the first 24 h after ROSC [80] . Among several studies, all 108 patients with absent pupillary light responses at day 3 after ROSC had poor outcomes (death, vegetative state, or severe disability with total dependency 3-6 months after arrest), giving a false positive rate of 0% [95% confidence interval (CI) 0-3] [79 ]. The absence of a corneal reflex or motor response to painful stimuli at day 3 after ROSC also predicts a poor outcome with a false positive rate of 0% and upper 95% CI limit of approximately 9% depending on the study [8 ,79 ] . Myoclonic status epilepticus (characterized by bilateral, synchronous twitches of limb, trunk, or facial muscles) reliably predicts a poor outcome at 24 h after ROSC [no false positives (95% CI 0-14)] [79 ,81], but it can be misdiagnosed by nonneurologists [82 ] . Burst suppression or generalized epileptiform discharges on the electroencephalogram predict poor outcome, but this is too imprecise for use in individual cases. Bilateral absence of the N20 component of the somatosensory-evoked potential (SSEP) with median nerve stimulation recorded on days 1-3 or later accurately predicts a poor outcome [no false positives (95% CI 0-2)] [79 ]. MRI may contribute to prognostication in comatose postcardiac arrest patients [83, 84] , but at the moment, there are too few data to determine its precise value in predicting outcome.
The biomarkers NSE and serum S-100B have been proposed as potentially useful tools for prognostication, but these assays are not commonly available [79 ] . In 13 comatose patients resuscitated from OHCA, high concentrations of interleukin (IL)-8 and IL-6 in the cerebrospinal fluid were associated with poor neurological outcome [85] .
The effect of therapeutic hypothermia on the predicative tests for prognostication is uncertain. In 77 consecutive comatose patients admitted after CPR, all 13 patients with bilateral absence of the N20 component of the SSEP during hypothermia had a poor neurologic outcome at 30 days, giving a positive predictive value of 1.00 (95% CI 0.77-1.00) [86 ] . In 90 patients following OHCA and therapeutic hypothermia, an increase in NSE values between 24 and 48 h and NSE values at 48 h was a specific but only moderately sensitive predictor of poor outcome [87 ] . NSE seems to be a better marker than serum S-100B for predicting outcome after cardiac arrest and therapeutic hypothermia [88 ] . Bispectral index (BIS) monitoring has been studied for prognostication in cardiac arrest survivors: in a recent study [89 ] , all 14 postcardiac arrest patients who had BIS values of zero had a bad neurological outcome after cardiac arrest and induced hypothermia. In another study [90 ] of 83 patients treated with hypothermia, a BIS value of less than 22 predicted poor neurological outcome at hospital discharge with an area under the receiver-operating characteristic curve of 0.91 (95% CI 0.85-0.98). In other recent studies, two of 14 patients who had been treated with hypothermia and had motor responses no better than extension at day 3 regained awareness [91], and six comatose survivors of cardiac arrest who had been treated with hypothermia improved beyond vegetative state despite developing postanoxic status epilepticus [92 ] . There is an emerging consensus among experts that after hypothermia therapy, prognostication (particularly when based on the motor response) should probably be delayed until at least 3 days after normothermia has been restored.
Organ donation
Up to 16% of patients who achieve sustained ROSC after cardiac arrest develop clinical brain death and can be considered for organ donation [93] . Transplant outcomes from the use of these organs are similar to those achieved with organs from other brain-dead donors [93] . One group has reported excellent transplanted kidney function in recipients receiving organs from uncontrolled 
Outcome after admission to ICU
There is evidence of considerable variation between hospitals in outcomes of patients admitted to ICUs after cardiac arrest [6 ,7 ]. Among 4674 postcardiac arrest patients admitted to ICUs in 39 hospitals in the United States, there was lower mortality among those admitted to ICUs that treated a high volume of postcardiac arrest patients [7 ] . This has important implications for the potential development of specialist cardiac arrest centres.
Conclusion
Survivors from cardiac arrest develop a PCAS that comprises postcardiac arrest brain injury, postcardiac arrest myocardial dysfunction, the systemic ischaemia/reperfusion response, and the persistent precipitating disease. A postresuscitation care bundle that includes therapeutic hypothermia, primary PCI, and control of blood sugar improves survival and neurological outcome in cardiac arrest survivors [8 ,95] . Predicting outcome in comatose survivors of cardiac arrest requires caution because the effect of therapeutic hypothermia on the tests used for prognostication is uncertain.
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